The project will expand our cohort of stem cells from previously subtyped patients to capture the broad heterogeneity of Alzheimer’s and represent ethnically diverse populations, which will establish the largest ancestrally diverse collection of human iPSC models capturing the molecular heterogeneity of late-onset AD. This transformative resource will be shared broadly with qualified recipients engaged in AD research programs. With this critical groundwork, we and the broader AD research community will be able to perform large-scale disease phenotyping to investigate patient subtypes and design targeted drug screens, fueling the discovery of new candidate precision therapies for AD.
In sum, this project will serve to establish stem cell models as a large-scale platform for predictive Alzheimer’s subtyping and precision drug discovery. We envision that this resource will not only help to predict patient subtypes and select the right drug targets, but also to ultimately streamline clinical trial design by ensuring we test the most promising drugs on the most suitable candidates, leading to effective precision treatments and improved patient outcomes.